HLA Health HourMedicaid & MedicareInsuranceMental HealthNutritionFind a ProviderHealth JobsProvider Corner
ALERTS (5) ▾
Healthcare Markets
UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.
Saturday, November 21, 2026
Edition
HELPHEALTHLINK BRIEF
HLA Network News
HealthLink of America
HEALTHLINK OF AMERICA NEWS / RESOURCES
NORTH CAROLINA HEALTH PLANS
NC MedicaidMedicareBlue Cross NCHealthy BlueAmeriHealth Caritas NCCarolina Complete HealthUnitedHealthcare Community PlanWellCare of NCAlliance HealthTrillium Health ResourcesVaya PartnersAetnaHumanaCigna
All plans ›
ADVERTISEMENT
SAMPLE AD
Genius Eye TV
Free health and community TV, streaming now
Watch HLA Health Hour and local shows free on Genius Eye TV.
LEARN MORE
World Health · national

Experimental malaria antibody protects infants but may interfere with vaccine

A trial found L9LS protected infants during malaria season but weakened their immune response to R21 vaccine.

An experimental malaria antibody called L9LS provided strong protection to infants in Mali during the six-month malaria season, according to a clinical trial presented at the American Society of Tropical Medicine and Hygiene annual meeting. However, the antibody appeared to interfere with how infants' immune systems responded to the R21 malaria vaccine, which is widely used in Mali.

The Phase Ib trial tested L9LS, a monoclonal antibody developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), in infants as young as one month old. Researchers wanted to test the antibody in very young children because they cannot receive malaria vaccines until at least five months old, leaving them vulnerable during peak malaria transmission times.

The antibody protected infants with 78% efficacy against malaria infection and was safe, according to the trial results. However, because it interfered with the R21 vaccine's effectiveness, researchers said they are pausing plans for a larger trial with infants. The antibody had shown a strong safety and effectiveness record in earlier trials with older children in Mali and Kenya.

Researchers said they will continue studying whether L9LS could help protect children who remain at risk of malaria after they have completed the R21 vaccine series.

What it means in Raleigh

RALEIGH HEALTH SYSTEM
State agency: NC Department of Health and Human Services (NCDHHS)
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.

Sources

Not medical advice. HLA Network News reports health news. Talk to your doctor or care team about your own care. In a crisis, call or text 988. In an emergency, call 911.
ADVERTISEMENT
Ad e2e308773
E2E Clinic e2e308773